C4 Therapeutics, Inc. SEC filings CCCC
C4 Therapeutics, Inc. has 546 filings in SEC EDGAR's recent list, going back to Jan 11, 2016. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Apr 29, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 25, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 25, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 11, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change
|
May 15, 2026 | May 15, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Apr 10, 2026 | Apr 10, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Apr 9, 2026 | Apr 9, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 14, 2026 | Jan 14, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement
|
Oct 16, 2025 | Oct 16, 2025 |
| 8-K |
Current report
Other events
|
Oct 16, 2025 | Oct 16, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 1, 2025 | Oct 1, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 22, 2025 | Sep 22, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 18, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
May 7, 2025 | May 7, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 14, 2025 | Apr 14, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 14, 2025 | Jan 14, 2025 |
| 8-K |
Current report
Other events
|
Dec 9, 2024 | Dec 9, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 20, 2024 | Nov 20, 2024 |
| 8-K |
Current report
Results of operations
|
Oct 31, 2024 | Oct 31, 2024 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Oct 16, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 15, 2024 | Oct 15, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 11, 2024 | Oct 11, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 3, 2024 | Sep 3, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 1, 2024 | Aug 1, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 21, 2024 | Jun 21, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 10, 2024 | Jun 10, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Officer or director change
|
Mar 8, 2024 | Mar 8, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 4, 2024 | Mar 4, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2024 | Feb 22, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 11, 2024 | Jan 11, 2024 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure
|
Jan 9, 2024 | Jan 9, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 12, 2023 | Dec 12, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Dec 12, 2023 | Dec 12, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Nov 20, 2023 | Nov 20, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 1, 2023 | Nov 1, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 5, 2023 | Sep 5, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2023 | Aug 8, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 20, 2023 | Jun 20, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
May 30, 2023 | May 29, 2023 |
| 8-K |
Current report
Results of operations
|
May 4, 2023 | May 4, 2023 |
| 8-K/A |
Amended current report
Results of operations
|
Feb 23, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 23, 2023 | Feb 23, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 2, 2023 | Jan 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2022 | Nov 3, 2022 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Sep 22, 2022 | Jun 22, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2022 | Aug 4, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 2, 2022 | Jul 29, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2022 | Jun 22, 2022 |
| 8-K |
Current report
Officer or director change
|
Jun 17, 2022 | Jun 15, 2022 |
| 8-K |
Current report
Other events
|
May 16, 2022 | May 16, 2022 |
| 8-K |
Current report
Results of operations
|
May 5, 2022 | May 5, 2022 |
| 8-K |
Current report
Other events
|
Apr 8, 2022 | Apr 8, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 16, 2022 | Mar 10, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 24, 2022 | Feb 24, 2022 |
| 8-K/A | Amended current report | Jan 21, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Nov 30, 2021 | Nov 24, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 11, 2021 | Aug 11, 2021 |
| 8-K |
Current report
Shareholder vote results, Regulation FD disclosure
|
Jun 21, 2021 | Jun 15, 2021 |
| 8-K |
Current report
Other events
|
Jun 14, 2021 | Jun 14, 2021 |
| 8-K |
Current report
Other events
|
Jun 7, 2021 | Jun 7, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
May 26, 2021 | May 26, 2021 |
| 8-K |
Current report
Officer or director change
|
May 20, 2021 | May 20, 2021 |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 8-K |
Current report
Officer or director change
|
Apr 30, 2021 | Apr 27, 2021 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Mar 11, 2021 | Mar 10, 2021 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 12, 2021 | Jan 6, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 6, 2021 | Jan 6, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 19, 2020 | Nov 18, 2020 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2020 | Nov 12, 2020 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Oct 6, 2020 | Oct 1, 2020 |
Showing 79 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CCCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662579
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.